Compare Ecolab Inc. (ECL) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Sana Biotechnology Inc — how do they compare? Ecolab Inc. trades at $280.7 (market cap $79.79B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Ecolab Inc. is far larger — about 70.6× Sana Biotechnology Inc's market cap, and Ecolab Inc. pays a 1.03% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ECL | SANA | |
|---|---|---|
Market Cap | $79.79B | $1.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $308.35 | $5.92 |
52-Week Low | $245.73 | $2.68 |
Enterprise Value | $88.57B | $1.05B |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $281.17, down 1.14% on the day, with a bullish technical signal from moving averages and strong institutional interest. The company reported Q2 2026 EPS of $2.09, beating estimates, and raised full-year guidance to $8.05-$8.25. Revenue growth remains steady at 5% organic, supported by pricing gains and volume increases. Valuation ratios are elevated with a P/E of 38.21, reflecting premium pricing for consistent performance.
Outlook is positive with a consensus price target of $327.90, implying 16.6% upside. Risks include high valuation sensitivity and rising input costs. The stock offers growth potential from digital expansion and recent CoolIT acquisition, but investors should monitor margin pressures and debt levels.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
